|Post IPO Valuation|
|Debt, 11/2013 |
In the short period since Iroko was founded in 2007, we have assembled a portfolio of proven pharmaceuticals, especially prescription pain medicines. Our goal has been to bring new life to these trusted products—new geographic markets, new indications, and new benefits through further development enabled by new technology.
We have already extended a distribution and sales network across more than 40 countries. And we have developed an industry-leading pipeline of nano-formulated lower-dose NSAIDs to address the need for new options in pain management.
Experience. Marketed products. A global presence. Innovation.
That’s Iroko. We’re an established company. And we’re hurrying to improve healthcare.